

SmartcholTM







Smartchol^m

For Cholestrol Management



Cardiovascular disease (CVD) is a leading cause of mortality and is responsible for the deaths of 17 million people each year, approximately one-third of all global deaths annually. Of the estimated 16.6 million deaths attributed to CVD worldwide, 80% is in developing countries. About 75% of the mortality among diabetic men, and 57% among diabetic women, is attributed to cardiovascular disease.

Higher concentrations of Low Density Lipoprotein (LDL) and lower concentrations of functional High Density Lipoprotein (HDL) have been found to be associated with cardiovascular disease as these promote atherosclerosis, leading to myocardial infarction and stroke.

As a first line of intervention as well as during treatment conditions with cholesterol reducing drugs, changes to the lifestyle are recommended. In the recent past functional foods fortified with plant based bioactives and dietary supplements have found increasing focus as adjuvant in cholesterol management.

Smartchol

TABLE OF CONTENTS

SmartChol™ Scientific Perspective	04
SmartChol™ Developmental Strategy	05
Origin of SmartChol™	06
Pharmacognosy Analysis	06
How SmartChol™ Works	07
SmartChol™ Metabolite Fingerprinting	07
Cell assays on SmartChol™	08
Pre-clinical Efficacy of SmartChol™	09
Safety of SmartChol™	10
Patent and Trademark	10
Manufacturing of SmartChol™	11
SmartChol™ – For Cholesterol management	12
References	12

Smartchol[™] has been reducing cholestrol and triglycerides, thereby managing cardio vascular health

Scientific Perspectives

SmartCholTM has shown efficacy in cholesterol management and has been thoroughly characterized using metabolite fingerprinting and by testing physical and chemical safety parameters. Animal studies on Hypercholesterolemic Sprague dawley rats have shown SmartCholTM is efficacious in lowering plasma triglyceride and total cholesterol while increased HDL-Cholesterol at concentration of 100 mg/kg body weight.

The safety and toxicity studies showed that SmartChol[™] is non-toxic to rats at dose levels of 2000 mg/kg body weight and 5000 mg/kg body weight. Therefore, the LD50 of SmartChol[™] is expected to exceed 5000 mg/kg body weight.

Safety and Efficacy studies have proven SmartChol™ as potential lead in Dyslipidemia management.

Avesthagen Limited 05

Smartchol[™] - Developmental Strategy

